Cardiac effects appeared common while strokes were not, mortality improved, a monoclonal antibody treatment showed benefit in outpatients, and data varied on duration of antibody response, among other recent findings on COVID-19.
A randomized trial did not find benefit from tocilizumab, and the results were mixed from a smaller trial and retrospective analyses. An editorialist said that evidence does not yet support routine use of the drug for COVID-19 and suggested
Submit your short article about a strategy, patient or colleague interaction, or other aspect of hospital practice during the pandemic by Aug. 31, and it may be published in the November ACP Hospitalist.
Recent studies showed that convalescent plasma didn't improve outcomes, a protocol reduced intubation rates, delirium was a common presentation among elderly patients, venous thromboembolism (VTE) was more common in the ICU, and racial disparities
The percentage of urine tests that were positive for illicit drugs increased, an ED saw more nonfatal opioid overdoses, and experts offered hospitalist-specific advice on handling substance use disorders.
The July ACP Hospitalist is online and in the mail, with tips from the front lines on surviving COVID-19, additional articles about the pandemic, and a special focus on care for inpatients with addiction.
Among other news this week, the NIH and the WHO released results from remdesivir trials, more negative findings were published for hydroxychloroquine, and ACP and Annals of Internal Medicine held a vaccine forum featuring Anthony S. Fauci, MD, MACP,
Clinicians and health departments throughout the U.S. should be prepared to detect and manage cases of Middle East respiratory syndrome coronavirus (MERS-CoV), the CDC recently warned.
Flu testing and treatment advice came from the NIH, convalescent plasma failed in a trial, new studies suggested looking out for myocardial injury and not overdoing thromboprophylaxis, and remdesivir got full approval, among other COVID-19 news.
The FDA issued an emergency use authorization for the first mRNA vaccine against SARS-CoV-2, and the CDC's Advisory Committee on Immunization Practices made an interim recommendation for its use in those ages 16 years and older. New research looked